Skip to content

A Feasibility Study of a Fecal Incontinence Management System for Medical Use

A Feasibility Study of a Fecal Incontinence Management System for Medical Use

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00556972
Enrollment
4
Registered
2007-11-12
Start date
2008-01-31
Completion date
2008-04-30
Last updated
2022-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fecal Incontinence

Brief summary

The purpose of this feasibility study is to evaluate the performance and skin-friendliness of the barrier of the Fecal Incontinence Management System. The investigator will complete a questionnaire for each of the tested products and the products will be evaluated as regards leakage, wear time, and skin-friendliness.

Detailed description

The purpose of this feasibility study is to evaluate the performance and skin-friendliness of the barrier of the Fecal Incontinence Management System. The investigator will complete a questionnaire for each of the tested products and the products will be evaluated as regards leakage, wear time, and skin-friendliness

Interventions

DEVICEFecal Incontinence Management System

The device is intended to remedy fecal incontinence.

Sponsors

Coloplast A/S
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The subject is at least 18 years of age * The subject has fecal incontinence

Exclusion criteria

* The subject is pregnant and/or breastfeeding * The subject has perianal fistulas and/or hemorrhoids * It's estimated that the subject's perianal skin makes it inappropriate for subject to participate in the study (i.e. in case of damaged skin, very sweaty skin or very sinuous and folded skin)

Design outcomes

Primary

MeasureTime frame
The Primary Outcome Measure is Device Wear Time (Time From the Device is Applied Until it is Removed)5 days

Secondary

MeasureTime frameDescription
Is the Barrier Size and Shape SatisfactorySubjects were followed for the duration of the study, an average of 23 hoursPercentage of subjects who answered yes to the question: is the barrier size and shape satisfactory
Assessment of Skin 0-2 Inches From the Edge of the AnusSubjects were evaluated before and after testSkin condition scale: 1 = Normal skin without redness, 2 = Normal redness and intact skin, 3 = Abnormal redness but intact skin, 4 = Red and spotted but intact skin, 5 = Red and broken skin, 6 = Broken and bleeding skin Best skin condition score is 1, and worst skin condition score is 6.
What is Your Assessment of the Ease of Correct Application of the Anal Adhesive?After application of product

Countries

United States

Participant flow

Participants by arm

ArmCount
Fecal Incontinence Management System
The product is a management system for use in fecal incontinence. It consists of a barrier with an attached pouch and a Bed Drainage Bag.
4
Total4

Baseline characteristics

CharacteristicFecal Incontinence Management System
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
2 Participants
Age, Categorical
Between 18 and 65 years
2 Participants
Age, Continuous62.0 years
STANDARD_DEVIATION 14.2
Region of Enrollment
United States
4 participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
1 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 4
serious
Total, serious adverse events
0 / 4

Outcome results

Primary

The Primary Outcome Measure is Device Wear Time (Time From the Device is Applied Until it is Removed)

Time frame: 5 days

Population: ITT

ArmMeasureValue (MEAN)Dispersion
Fecal Incontinence Management SystemThe Primary Outcome Measure is Device Wear Time (Time From the Device is Applied Until it is Removed)23.1 HoursStandard Deviation 0.7
Secondary

Assessment of Skin 0-2 Inches From the Edge of the Anus

Skin condition scale: 1 = Normal skin without redness, 2 = Normal redness and intact skin, 3 = Abnormal redness but intact skin, 4 = Red and spotted but intact skin, 5 = Red and broken skin, 6 = Broken and bleeding skin Best skin condition score is 1, and worst skin condition score is 6.

Time frame: Subjects were evaluated before and after test

Population: ITT

ArmMeasureGroupValue (MEAN)Dispersion
Fecal Incontinence Management SystemAssessment of Skin 0-2 Inches From the Edge of the AnusBefore test2.25 Scores on a scaleStandard Deviation 1.89297
Fecal Incontinence Management SystemAssessment of Skin 0-2 Inches From the Edge of the AnusAfter test3.25 Scores on a scaleStandard Deviation 2.62996
Secondary

Is the Barrier Size and Shape Satisfactory

Percentage of subjects who answered yes to the question: is the barrier size and shape satisfactory

Time frame: Subjects were followed for the duration of the study, an average of 23 hours

Population: ITT

ArmMeasureValue (NUMBER)
Fecal Incontinence Management SystemIs the Barrier Size and Shape Satisfactory100 Percentage of subjects
Secondary

What is Your Assessment of the Ease of Correct Application of the Anal Adhesive?

Time frame: After application of product

ArmMeasureGroupValue (NUMBER)
Fecal Incontinence Management SystemWhat is Your Assessment of the Ease of Correct Application of the Anal Adhesive?Very difficult0 Pouche and Bag
Fecal Incontinence Management SystemWhat is Your Assessment of the Ease of Correct Application of the Anal Adhesive?Difficult1 Pouche and Bag
Fecal Incontinence Management SystemWhat is Your Assessment of the Ease of Correct Application of the Anal Adhesive?Reasonable0 Pouche and Bag
Fecal Incontinence Management SystemWhat is Your Assessment of the Ease of Correct Application of the Anal Adhesive?Easy6 Pouche and Bag
Fecal Incontinence Management SystemWhat is Your Assessment of the Ease of Correct Application of the Anal Adhesive?Very Easy0 Pouche and Bag

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026